AIMS/HYPOTHESIS: The aim of this study was to investigate the effects of lifestyle intervention on the levels of plasminogen activator inhibitor (PAI-1) and fibrinogen in subjects participating in the Finnish Diabetes Prevention Study (DPS). METHODS: In five DPS centres, 321 subjects with impaired glucose tolerance (intervention group, n=163; control group, n=158) had theirPAI-1 and fibrinogen levels measured at baseline and at the 1-year follow-up. Additional 3-year follow-up assessments were carried out in a sample of 97 subjects in one of the DPS centres (Turku). The intervention programme included an intensive lifestyle intervention aiming at weight reduction, healthy diet and increased physical activity. RESULTS: During the first intervention year, PAI-1 decreased by 31% in the intervention group but showed no change in the control group (p<0.0001). In the Turku subgroup, the decrease in PAI-1 persisted throughout the 3-year follow-up. Changes in PAI-1 were associated with the number of lifestyle changes made during the first year (p=0.008). Weight reduction was the most important factor explaining the decrease in PAI-1. Changes in fibrinogen levels did not differ between the groups. CONCLUSIONS/ INTERPRETATION: In addition to the previously reported reduction in the risk of type 2 diabetes in DPS participants with impaired glucose tolerance, the intensive dietary and exercise intervention had beneficial long-term effects on fibrinolysis as indicated by the reduced levels of PAI-1. These results suggest that elevated PAI-1 levels in obese subjects with impaired glucose tolerance are mostly reversible by lifestyle changes, especially those geared to weight reduction.
RCT Entities:
AIMS/HYPOTHESIS: The aim of this study was to investigate the effects of lifestyle intervention on the levels of plasminogen activator inhibitor (PAI-1) and fibrinogen in subjects participating in the Finnish Diabetes Prevention Study (DPS). METHODS: In five DPS centres, 321 subjects with impaired glucose tolerance (intervention group, n=163; control group, n=158) had their PAI-1 and fibrinogen levels measured at baseline and at the 1-year follow-up. Additional 3-year follow-up assessments were carried out in a sample of 97 subjects in one of the DPS centres (Turku). The intervention programme included an intensive lifestyle intervention aiming at weight reduction, healthy diet and increased physical activity. RESULTS: During the first intervention year, PAI-1 decreased by 31% in the intervention group but showed no change in the control group (p<0.0001). In the Turku subgroup, the decrease in PAI-1 persisted throughout the 3-year follow-up. Changes in PAI-1 were associated with the number of lifestyle changes made during the first year (p=0.008). Weight reduction was the most important factor explaining the decrease in PAI-1. Changes in fibrinogen levels did not differ between the groups. CONCLUSIONS/ INTERPRETATION: In addition to the previously reported reduction in the risk of type 2 diabetes in DPSparticipants with impaired glucose tolerance, the intensive dietary and exercise intervention had beneficial long-term effects on fibrinolysis as indicated by the reduced levels of PAI-1. These results suggest that elevated PAI-1 levels in obese subjects with impaired glucose tolerance are mostly reversible by lifestyle changes, especially those geared to weight reduction.
Authors: David E Laaksonen; Jaana Lindström; Timo A Lakka; Johan G Eriksson; Leo Niskanen; Katja Wikström; Sirkka Aunola; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Timo T Valle; Pirjo Ilanne-Parikka; Anne Louheranta; Helena Hämäläinen; Merja Rastas; Virpi Salminen; Zygimantas Cepaitis; Martti Hakumäki; Hannu Kaikkonen; Pirjo Härkönen; Jouko Sundvall; Jaakko Tuomilehto; Matti Uusitupa Journal: Diabetes Date: 2005-01 Impact factor: 9.461
Authors: R Zanettini; D Bettega; O Agostoni; B Ballestra; G del Rosso; R di Michele; P M Mannucci Journal: Cardiology Date: 1997 Sep-Oct Impact factor: 1.869
Authors: L H Kuller; P Velentgas; J Barzilay; N J Beauchamp; D H O'Leary; P J Savage Journal: Arterioscler Thromb Vasc Biol Date: 2000-03 Impact factor: 8.311
Authors: Jaana Lindström; Anne Louheranta; Marjo Mannelin; Merja Rastas; Virpi Salminen; Johan Eriksson; Matti Uusitupa; Jaakko Tuomilehto Journal: Diabetes Care Date: 2003-12 Impact factor: 19.112
Authors: M Cigolini; G Targher; I A Bergamo Andreis; M Tonoli; G Agostino; G De Sandre Journal: Arterioscler Thromb Vasc Biol Date: 1996-03 Impact factor: 8.311
Authors: L Maria Belalcazar; Christie M Ballantyne; Wei Lang; Steven M Haffner; Julia Rushing; Dawn C Schwenke; F Xavier Pi-Sunyer; Russell P Tracy Journal: Arterioscler Thromb Vasc Biol Date: 2011-04-21 Impact factor: 8.311
Authors: Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan Journal: Nat Clin Pract Endocrinol Metab Date: 2008-05-20
Authors: L Maria Belalcazar; Andrea M Anderson; Wei Lang; Dawn C Schwenke; Steven M Haffner; Hiroshi Yatsuya; Julia Rushing; Mara Z Vitolins; Rebecca Reeves; F Xavier Pi-Sunyer; Russell P Tracy; Christie M Ballantyne Journal: J Acad Nutr Diet Date: 2014-08-15 Impact factor: 4.910
Authors: Su-Jung Cho; Un Ju Jung; Hae-Jin Park; Hye-Jin Kim; Yong Bok Park; Sang Ryong Kim; Myung-Sook Choi Journal: Evid Based Complement Alternat Med Date: 2013-04-18 Impact factor: 2.629
Authors: Ronald B Goldberg; Marinella G Temprosa; Kieren J Mather; Trevor J Orchard; Abbas E Kitabchi; Karol E Watson Journal: Diabetes Care Date: 2014-05-13 Impact factor: 19.112